Abstract:Objective To evaluate the difference between MRI and 11C-MET PET-CT for gross tumor volume (GTV) delineation in the precision radiotherapy for gliomas. Methods Six patients with a pathologically confirmed diagnosis of gliomas were selected for target delineation. Five physicians in our department were called to delineate the GTV based on the preoperative MRI and 11C-MET PET-CT images of these patients. The GTVs based on the two methods were compared. Results There was no significant difference between the GTVs based on MRI and 11C-MET PET-CT (P=0.917), and their coefficients of variation were also similar (P=0.600). The coincidences of GTVs were different among the patients, with a maximum value of 73.0% and a minimum value of 51.8%. GTV showed no significant difference when defined by different physicians on MRI and PET-CT (P=0.709);the biggest difference was 27.66 cm3 on PET-CT and 40.37 cm3 on MRI. Conclusions The boundaries of gliomas defined on MRI and PET-CT are different. The GTVs delineated by different physicians on MRI and PET-CT are similar, and the biggest difference on PET-CT is smaller than that on MRI, which suggests that 11C-MET PET-CT is a more direct way for displaying GTV.
. Comparative evaluation of 11C-MET PET-CT and MRI for GTV delineation in precision radiotherapy for gliomas[J]. Chinese Journal of Radiation Oncology, 2014, 23(2): 143-90.
[1] Niyazi M, Geisler J, Siefert A, et al. FET-PET-CT for malignant glioma treatment planning[J]. Radiother Oncol,2011,99:44-48. [2] Scoccianti S, Magrini SM, Ricardi U, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007:a multicenter study by the Central Nervous System Study Group of IARO (Italian Association of Radiation Oncology)[J].Neurosurgery,2010,67:446-458. [3] Chiti A, Kirienko M, Gregoire V. Clinical use of PET-CT/CT data for radiotherapy planning:what are we looking for[J]? Radiother Oncol,2010,96:277-279. [4] 杨荣水,吴华,潘卫民.功能成像在肿瘤生物适形调强放疗中的应用进展[J].国际医学放射学杂志,2010,33:235-239. [5] Pauleit D, Floeth F, Hamacher K, et al. O-(2-18F-fluoroethy)-L-tyrosine PET-CT combined with MRI improves the diagnostic assessment of cerebral gliomas[J]. Brain,2005,128:678-687. [6] Ortega-López N, Mendoza-Vásquez RG, Adame-Ocampo G, et al. Validation of MRI and 18F-FDG PET-CT coregistration in patients with primary brain tumors[J].Gac Med Mex,2007,143:309-316. [7] Gregoire V, Chiti A. PET-CT in radiotherapy planning:particularly exquisite test or pending and experimental tool[J]? Radiother Oncol,2010,96:275-276. [8] Chen W. Clinical applications of PET-CT in brain tumors. J Nucl Med,2007,48:1468-1481. [9] Goldman S. PET-CT for diagnosis and therapy of brain tumors[J]. Med Nucl,2011,35:347-351. [10] Anca-Ligia G, Sabrina TA, Eva R, et al. An interindividual comparison of O-(2-[18F]fluoroethy-L-tyrosine (FET)-and L-[methyl-11C]methionine (MET)-PET-CT in Patients with brain gliomas and metastases[J]. Int J Radiat Oncol Biol Phys,2011,63:142-145. [11] Mahasittiwat P, Mizoe JE, Hasegawa A, et al. L-[METHYL-(11) C]methionine positron emission tomography for target delineation in malignant gliomas:impact on results of carbon ion radiotherapy[J]. Int J Radiat Oncol Biol Phys,2008,70:515-522. [12] Galldiks N, Ullrich R, Schroeter M, et al. Volumetry of[11C]-methionine PET-CT uptake and MRI contrast enchancement in patients with recurrent glioblastoma multiforme[J]. Eur J Nucl Med Imaging,2010,37:84-92. [13] Miwak K, Shinada J, Yano H. Discrepancy between lesion distribution on methionine PET-CT and MR images in patients with glioblastoma multiforme:insight from a PET-CT and MR fusion image study[J]. Psychiatry,2004,75:1457-1462. [14] Niyazi M, Gessler J, Siefert A, et al. FET-PET-CT for malignant glioma treatment planning[J]. Radiother Oncol,2011,99:44-48. [15] Chao KS, Bhide S, Chen H,et al. Reduce in variation and improve efficiency of target volume delineation by a computer-assisted system using a deformable image registration approach[J]. Int J Radiat Oncol Biol Phys,2007,68:1512-1521.